HK1162520A1 - Pyrrolotriazines as alk and jak2 inhibitors alk jak2 - Google Patents

Pyrrolotriazines as alk and jak2 inhibitors alk jak2

Info

Publication number
HK1162520A1
HK1162520A1 HK12103270.1A HK12103270A HK1162520A1 HK 1162520 A1 HK1162520 A1 HK 1162520A1 HK 12103270 A HK12103270 A HK 12103270A HK 1162520 A1 HK1162520 A1 HK 1162520A1
Authority
HK
Hong Kong
Prior art keywords
alk
jak2
pyrrolotriazines
inhibitors
jak2 inhibitors
Prior art date
Application number
HK12103270.1A
Other languages
English (en)
Chinese (zh)
Inventor
Henry J Breslin
Sankar Chatterjee
James L Diebold
Bruce D Dorsey
Derek Dunn
Diane E Gingrich
Greg A Hostetler
Robert L Hudkins
Rachael Hunter
Kurt Josef
Joseph Lisko
Eugen F Mesaros
Karen L Milkiewicz
Gregory R Ott
Babu G Sundar
Jay P Theroff
Tho Thieu
Rabindranath Tripathy
Theodore L Underiner
Linda Weinberg
Gregory J Wells
Craig A Zificsak
Original Assignee
Cephalon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cephalon Inc filed Critical Cephalon Inc
Publication of HK1162520A1 publication Critical patent/HK1162520A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
HK12103270.1A 2008-12-19 2012-04-02 Pyrrolotriazines as alk and jak2 inhibitors alk jak2 HK1162520A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US13954508P 2008-12-19 2008-12-19

Publications (1)

Publication Number Publication Date
HK1162520A1 true HK1162520A1 (en) 2012-08-31

Family

ID=41683065

Family Applications (1)

Application Number Title Priority Date Filing Date
HK12103270.1A HK1162520A1 (en) 2008-12-19 2012-04-02 Pyrrolotriazines as alk and jak2 inhibitors alk jak2

Country Status (7)

Country Link
US (1) US8471005B2 (xx)
EP (1) EP2376491B1 (xx)
AR (1) AR074830A1 (xx)
ES (1) ES2539620T3 (xx)
HK (1) HK1162520A1 (xx)
TW (1) TW201035100A (xx)
WO (1) WO2010071885A1 (xx)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3409278T3 (pl) 2011-07-21 2021-02-22 Sumitomo Pharma Oncology, Inc. Heterocykliczne inhibitory kinazy białkowej
WO2014110574A1 (en) 2013-01-14 2014-07-17 Incyte Corporation Bicyclic aromatic carboxamide compounds useful as pim kinase inhibitors
ES2790419T3 (es) 2013-01-15 2020-10-27 Incyte Holdings Corp Los compuestos de tiazolcarboxamidas y piridinacarboxamida útiles como inhibidores de quinasa de PIM
WO2014118388A1 (en) 2013-02-04 2014-08-07 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for assaying jak2 activity in red blood cells and uses thereof
WO2014193932A1 (en) 2013-05-29 2014-12-04 Cephalon, Inc. Pyrrolotriazines as alk inhibitors
US9556197B2 (en) 2013-08-23 2017-01-31 Incyte Corporation Furo- and thieno-pyridine carboxamide compounds useful as pim kinase inhibitors
US9822124B2 (en) 2014-07-14 2017-11-21 Incyte Corporation Bicyclic heteroaromatic carboxamide compounds useful as Pim kinase inhibitors
US9580418B2 (en) 2014-07-14 2017-02-28 Incyte Corporation Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors
US10158988B2 (en) * 2014-07-24 2018-12-18 Qualcomm Incorporated Multi-SIM based device auto configuration system and process
US10329295B2 (en) 2015-03-12 2019-06-25 Merck Sharp & Dohme Corp. Pyrrolotriazine inhibitors of IRAK4 activity
EP3268367B8 (en) 2015-03-12 2022-11-16 Merck Sharp & Dohme LLC Carboxamide inhibitors of irak4 activity
US9840503B2 (en) 2015-05-11 2017-12-12 Incyte Corporation Heterocyclic compounds and uses thereof
US9540347B2 (en) 2015-05-29 2017-01-10 Incyte Corporation Pyridineamine compounds useful as Pim kinase inhibitors
US9708333B2 (en) 2015-08-12 2017-07-18 Incyte Corporation Fused bicyclic 1,2,4-triazine compounds as TAM inhibitors
US10053465B2 (en) 2015-08-26 2018-08-21 Incyte Corporation Pyrrolopyrimidine derivatives as TAM inhibitors
TWI734699B (zh) 2015-09-09 2021-08-01 美商英塞特公司 Ｐｉｍ激酶抑制劑之鹽
US9920032B2 (en) 2015-10-02 2018-03-20 Incyte Corporation Heterocyclic compounds useful as pim kinase inhibitors
MA52119A (fr) 2015-10-19 2018-08-29 Ncyte Corp Composés hétérocycliques utilisés comme immunomodulateurs
SG11201804152RA (en) 2015-11-19 2018-06-28 Incyte Corp Heterocyclic compounds as immunomodulators
MA55194A (fr) 2015-12-22 2022-05-04 Incyte Corp Composés hétérocycliques en tant qu'immunomodulateurs
JP7034084B2 (ja) 2016-03-28 2022-03-11 インサイト・コーポレイション Ｔａｍ阻害剤としてのピロロトリアジン化合物
EP3452476B1 (en) 2016-05-06 2021-12-15 Incyte Corporation Heterocyclic compounds as immunomodulators
MA45116A (fr) 2016-05-26 2021-06-02 Incyte Corp Composés hétérocycliques comme immunomodulateurs
IL263825B (en) 2016-06-20 2022-08-01 Incyte Corp Heterocyclic compounds as immunomodulators
ES2930092T3 (es) 2016-07-14 2022-12-07 Incyte Corp Compuestos heterocíclicos como inmunomoduladores
US20180057486A1 (en) 2016-08-29 2018-03-01 Incyte Corporation Heterocyclic compounds as immunomodulators
EP3548496A4 (en) * 2016-12-01 2020-05-13 Aptose Biosciences Inc. PYRIMIDINE COMPOUNDS FUSED AS DUAL INHIBITORS OF BRD4 AND JAK2 AND METHODS OF USE THEREOF
ES2874756T3 (es) 2016-12-22 2021-11-05 Incyte Corp Derivados de triazolo[1,5-A]piridina como inmunomoduladores
ES2899402T3 (es) 2016-12-22 2022-03-11 Incyte Corp Derivados de piridina como inmunomoduladores
MY197635A (en) 2016-12-22 2023-06-29 Incyte Corp Benzooxazole derivatives as immunomodulators
HRP20221216T1 (hr) 2016-12-22 2022-12-23 Incyte Corporation Derivati tetrahidro imidazo[4,5-c]piridina kao induktori internalizacije pd-l1
US10954216B2 (en) 2016-12-27 2021-03-23 Riken BMP-signal-inhibiting compound
WO2018167283A1 (en) 2017-03-17 2018-09-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the diagnosis and treatment of pancreatic ductal adenocarcinoma associated neural remodeling
EP3610264A1 (en) 2017-04-13 2020-02-19 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the diagnosis and treatment of pancreatic ductal adenocarcinoma
HRP20220790T1 (hr) 2017-05-04 2022-09-16 Bayer Cropscience Aktiengesellschaft Derivati 2-{[2-(feniloksimetil)piridin-5-il]oksi}etanamina i srodni spojevi kao pesticidi, primjerice namijenjeni zaštiti bilja
MA50655B1 (fr) 2017-09-27 2021-11-30 Incyte Corp Sels de dérivés de pyrrolotriazine utiles en tant qu'inhibiteurs de tam
TW201924683A (zh) 2017-12-08 2019-07-01 美商英塞特公司 用於治療骨髓增生性贅瘤的低劑量組合療法
IL313101A (en) 2018-03-30 2024-07-01 Incyte Corp Heterocyclic compounds as immunomodulators
WO2019200254A1 (en) 2018-04-13 2019-10-17 Tolero Pharmaceuticals, Inc. Pim kinase inhibitors for treatment of myeloproliferative neoplasms and fibrosis associated with cancer
PT3790877T (pt) 2018-05-11 2023-05-10 Incyte Corp Derivados de tetrahidro-imidazo[4,5-c]piridina como imunomoduladores pd-l1
WO2020006408A1 (en) 2018-06-29 2020-01-02 Incyte Corporation Formulations of an axl/mer inhibitor
WO2020092015A1 (en) 2018-11-02 2020-05-07 University Of Rochester Therapeutic mitigation of epithelial infection
KR20210146290A (ko) 2019-02-12 2021-12-03 스미토모 다이니폰 파마 온콜로지, 인크. 헤테로시클릭 단백질 키나제 억제제를 포함하는 제제
CN112094272A (zh) * 2019-06-18 2020-12-18 北京睿熙生物科技有限公司 Cdk激酶抑制剂
KR20220042127A (ko) * 2019-06-28 2022-04-04 상하이 파마슈티컬스 홀딩 컴퍼니 리미티드 피라졸로피리미딘 화합물, 그의 제조 방법 및 그의 응용
MX2022001671A (es) 2019-08-09 2022-05-13 Incyte Corp Sales de un inhibidor de pd-1/pd-l1.
BR112022005826A2 (pt) 2019-09-30 2022-06-21 Incyte Corp Compostos de pirido[3,2-d]pirimidina como imunomoduladores
BR112022009031A2 (pt) 2019-11-11 2022-10-11 Incyte Corp Sais e formas cristalinas de um inibidor de pd-1/pd-l1
US11760756B2 (en) 2020-11-06 2023-09-19 Incyte Corporation Crystalline form of a PD-1/PD-L1 inhibitor
WO2022099071A1 (en) 2020-11-06 2022-05-12 Incyte Corporation Process for making a pd-1/pd-l1 inhibitor and salts and crystalline forms thereof
US11780836B2 (en) 2020-11-06 2023-10-10 Incyte Corporation Process of preparing a PD-1/PD-L1 inhibitor
CN115466264A (zh) * 2021-06-11 2022-12-13 腾讯科技（深圳）有限公司 吡咯并[2,1-f][1,2,4]三嗪类衍生物及其应用
KR20230081667A (ko) 2021-11-30 2023-06-07 연세대학교 산학협력단 단백질 키나아제 저해활성을 가지는 2, 7-치환된 피롤로[2,1-f][1,2,4]트라아진 화합물
AU2022401468A1 (en) * 2021-11-30 2024-06-20 Magicbullettherapeutics Co., Ltd. 2,7-substituted pyrrolo[2,1-f][1,2,4]triazine compound having protein kinase inhibitory activity
AU2023212957A1 (en) * 2022-01-25 2024-08-22 Kinnate Biopharma Inc. Inhibitors of cdk4/6 kinase
TW202412758A (zh) * 2022-06-29 2024-04-01 香港商英矽智能科技知識產權有限公司 Fgfr2與fgfr3抑制劑及其用途
WO2024097653A1 (en) 2022-10-31 2024-05-10 Sumitomo Pharma America, Inc. Pim1 inhibitor for treating myeloproliferative neoplasms

Family Cites Families (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4838925A (en) 1986-04-25 1989-06-13 E. I. Du Pont De Nemours And Company Heterocyclic acyl sulfonamides
WO1989000994A2 (en) 1987-07-31 1989-02-09 E.I. Du Pont De Nemours And Company Herbicidal sulfonamides
IT1269176B (it) 1994-01-11 1997-03-21 Isagro Srl Eterobicicli ad attivita' fungicida
SE9500051D0 (sv) 1995-01-09 1995-01-09 Frode Rise Antioxidants, tissue- and/or neuroprotectants
RU2331640C2 (ru) 1999-05-21 2008-08-20 Бристол-Маерс Сквибб Ко. Пирролтриазиновые ингибиторы киназ
JP4623483B2 (ja) 1999-08-23 2011-02-02 塩野義製薬株式会社 ｓＰＬＡ２阻害作用を有するピロロトリアジン誘導体
US6867300B2 (en) 2000-11-17 2005-03-15 Bristol-Myers Squibb Company Methods for the preparation of pyrrolotriazine compounds useful as kinase inhibitors
ATE318820T1 (de) 2000-11-17 2006-03-15 Bristol Myers Squibb Co Verfahren zur behandlung von mit p38-kinase assoziierten leiden und pyrrolotriazin- verbindungen als kinaseinhibitoren.
TW200300350A (en) 2001-11-14 2003-06-01 Bristol Myers Squibb Co C-5 modified indazolylpyrrolotriazines
EP1503996B1 (en) 2002-04-23 2008-12-24 Bristol-Myers Squibb Company Aryl ketone pyrrolo-triazine compounds useful as kinase inhibitors
PT1497019E (pt) 2002-04-23 2015-09-10 Bristol Myers Squibb Co Compostos de pirrolotriazina anilina úteis como inibidores de quinase
US7388009B2 (en) 2002-04-23 2008-06-17 Bristol-Myers Squibb Company Heteroaryl-substituted pyrrolo-triazine compounds useful as kinase inhibitors
TW200407143A (en) 2002-05-21 2004-05-16 Bristol Myers Squibb Co Pyrrolotriazinone compounds and their use to treat diseases
TWI329112B (en) 2002-07-19 2010-08-21 Bristol Myers Squibb Co Novel inhibitors of kinases
US6933386B2 (en) 2002-07-19 2005-08-23 Bristol Myers Squibb Company Process for preparing certain pyrrolotriazine compounds
EP1543009A4 (en) * 2002-08-02 2007-08-08 Bristol Myers Squibb Co Pyrrolotriazine KINASE INHIBITORS
HUE033832T2 (en) 2002-11-15 2018-01-29 Idenix Pharmaceuticals Llc 2'-methyl nucleosides in combination with interferon and Flaviviridae mutation
TW200420565A (en) 2002-12-13 2004-10-16 Bristol Myers Squibb Co C-6 modified indazolylpyrrolotriazines
WO2004072030A2 (en) 2003-02-05 2004-08-26 Bristol-Myers Squibb Company Process for preparing pyrrolotriazine kinase inhibitors
TW200508224A (en) 2003-02-12 2005-03-01 Bristol Myers Squibb Co Cyclic derivatives as modulators of chemokine receptor activity
WO2004087056A2 (en) 2003-03-28 2004-10-14 Scios Inc. BI-CYCLIC PYRIMIDINE INHIBITORS OF TGFβ
WO2005009389A2 (en) 2003-07-23 2005-02-03 Exelixis, Inc. Anaplastic lymphoma kinase modulators and methods of use
KR100904570B1 (ko) 2003-08-15 2009-06-25 노파르티스 아게 종양성 질환, 염증성 및 면역계 장애의 치료에 유용한2,4-피리미딘디아민
US7378409B2 (en) 2003-08-21 2008-05-27 Bristol-Myers Squibb Company Substituted cycloalkylamine derivatives as modulators of chemokine receptor activity
US7163937B2 (en) 2003-08-21 2007-01-16 Bristol-Myers Squibb Company Cyclic derivatives as modulators of chemokine receptor activity
US20060014741A1 (en) 2003-12-12 2006-01-19 Dimarco John D Synthetic process, and crystalline forms of a pyrrolotriazine compound
US7102001B2 (en) 2003-12-12 2006-09-05 Bristol-Myers Squibb Company Process for preparing pyrrolotriazine
MY145634A (en) 2003-12-29 2012-03-15 Bristol Myers Squibb Co Pyrrolotriazine compounds as kinase inhibitors
US7064203B2 (en) 2003-12-29 2006-06-20 Bristol Myers Squibb Company Di-substituted pyrrolotriazine compounds
JP4989233B2 (ja) 2004-02-14 2012-08-01 アイアールエム・リミテッド・ライアビリティ・カンパニー タンパク質キナーゼ阻害剤としての化合物および組成物
US7306631B2 (en) 2004-03-30 2007-12-11 The Procter & Gamble Company Keratin dyeing compounds, keratin dyeing compositions containing them, and use thereof
EP1730128A1 (en) 2004-03-31 2006-12-13 Exelixis, Inc. Anaplastic lymphoma kinase modulators and methods of use
UY28931A1 (es) 2004-06-03 2005-12-30 Bayer Pharmaceuticals Corp Derivados de pirrolotriazina utiles para tratar trastornos hiper-proliferativos y enfermedades asociadas con angiogenesis
US7102002B2 (en) 2004-06-16 2006-09-05 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
US20050288290A1 (en) 2004-06-28 2005-12-29 Borzilleri Robert M Fused heterocyclic kinase inhibitors
US7432373B2 (en) 2004-06-28 2008-10-07 Bristol-Meyers Squibb Company Processes and intermediates useful for preparing fused heterocyclic kinase inhibitors
US7439246B2 (en) 2004-06-28 2008-10-21 Bristol-Myers Squibb Company Fused heterocyclic kinase inhibitors
TW200600513A (en) 2004-06-30 2006-01-01 Bristol Myers Squibb Co A method for preparing pyrrolotriazine compounds
US7253167B2 (en) 2004-06-30 2007-08-07 Bristol-Myers Squibb Company Tricyclic-heteroaryl compounds useful as kinase inhibitors
US7102003B2 (en) 2004-07-01 2006-09-05 Bristol-Myers Squibb Company Pyrrolotriazine compounds
PE20060421A1 (es) 2004-08-12 2006-06-01 Bristol Myers Squibb Co Procedimiento para preparar un compuesto de pirrolotriazina anilina como inhibidores de cinasa
EP2364699A1 (en) 2004-09-13 2011-09-14 Eisai R&D Management Co., Ltd. Joint use of sulfonamide based compound with angiogenesis inhibitor
AR052771A1 (es) 2004-09-30 2007-04-04 Tibotec Pharm Ltd Pirimidinas biciclicas inhibidoras del vhc
JP2008516973A (ja) 2004-10-15 2008-05-22 タケダ サン ディエゴ インコーポレイテッド キナーゼ阻害剤
US7151176B2 (en) 2004-10-21 2006-12-19 Bristol-Myers Squibb Company Pyrrolotriazine compounds
TW200635927A (en) 2004-12-22 2006-10-16 Bristol Myers Squibb Co Synthetic process
US7456289B2 (en) 2004-12-31 2008-11-25 National Health Research Institutes Anti-tumor compounds
US7534882B2 (en) 2005-04-06 2009-05-19 Bristol-Myers Squibb Company Method for preparing pyrrolotriazine compounds via in situ amination of pyrroles
US20060235020A1 (en) 2005-04-18 2006-10-19 Soojin Kim Process for preparing salts of 4-[[5-[(cyclopropylamino)carbonyl]-2-methylphenyl]amino]-5-methyl-N-propylpyrrolo[2,1-f][1,2,4]triazine-6-carboxamide and novel stable forms produced therein
WO2006116016A2 (en) 2005-04-21 2006-11-02 The Regents Of The University Of California Molecular determinants of egfr kinase inhibitor response in glioblastoma
JO2787B1 (en) 2005-04-27 2014-03-15 امجين إنك, Alternative amide derivatives and methods of use
US20060257400A1 (en) 2005-05-13 2006-11-16 Bristol-Myers Squibb Company Combination therapy
WO2006130657A2 (en) 2005-05-31 2006-12-07 Bristol-Myers Squibb Company Stereoselective reduction process for the preparation of pyrrolotriazine compounds
US7619083B2 (en) 2005-07-01 2009-11-17 Bristol-Myers Squibb Company Intermediates useful in preparing certain pyrrolotriazine compounds and process for making such intermediates
US7405213B2 (en) 2005-07-01 2008-07-29 Bristol-Myers Squibb Company Pyrrolotriazine compounds useful as kinase inhibitors and methods of treating kinase-associated conditions therewith
US7402582B2 (en) 2005-07-01 2008-07-22 Bristol-Myers Squibb Company Pyrrolotriazine compounds useful as kinase inhibitors and methods of treating kinase-associated conditions therewith
WO2007004731A1 (ja) 2005-07-05 2007-01-11 Sumitomo Chemical Company, Limited 亜リン酸エステル類の結晶
JP5136945B2 (ja) 2005-07-05 2013-02-06 トヨタ自動車株式会社 燃料電池システム
EP1925941B1 (en) 2005-08-01 2012-11-28 Eisai R&D Management Co., Ltd. Method for prediction of the efficacy of vascularization inhibitor
US9006240B2 (en) 2005-08-02 2015-04-14 Eisai R&D Management Co., Ltd. Method for assay on the effect of vascularization inhibitor
CN101291934B (zh) 2005-09-27 2012-06-27 布里斯托尔-迈尔斯·斯奎布公司 [(1R),2S]-2-氨基丙酸2-[4-(4-氟-2-甲基-1H-吲哚-5-基氧基)-5-甲基吡咯并[2,1-f][1,2,4]三嗪-6-基氧基]-1-甲基乙基酯的晶型
US8431695B2 (en) 2005-11-02 2013-04-30 Bayer Intellectual Property Gmbh Pyrrolo[2,1-f][1,2,4]triazin-4-ylamines IGF-1R kinase inhibitors for the treatment of cancer and other hyperproliferative diseases
US7514435B2 (en) 2005-11-18 2009-04-07 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
US7348325B2 (en) 2005-11-30 2008-03-25 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
JP5249776B2 (ja) 2005-12-02 2013-07-31 バイエル・ヘルスケア・エルエルシー 過剰増殖性疾患および血管新生と関連する疾患を処置するために有用な置換された４−アミノ−ピロロトリアジン誘導体
PE20070855A1 (es) 2005-12-02 2007-10-14 Bayer Pharmaceuticals Corp Derivados de 4-amino-pirrolotriazina sustituida como inhibidores de quinasas
US8338594B2 (en) 2005-12-02 2012-12-25 Bayer Healthcare Llc Pyrrolotriazine derivatives useful for treating cancer through inhibition of aurora kinase
CN101370519B (zh) 2005-12-15 2013-07-24 阿斯利康(瑞典)有限公司 治疗癌症的促血管生成素-2拮抗剂和VEGF-A、KDR和/或Flt1拮抗剂的组合
US8063208B2 (en) 2006-02-16 2011-11-22 Bristol-Myers Squibb Company Crystalline forms of (3R,4R)-4-amino-1-[[4-[(3-methoxyphenyl)amino]pyrrolo[2,1-f][1,2,4]triazin-5-yl]methyl]piperidin-3-ol
EA200801945A1 (ru) 2006-03-07 2009-02-27 Бристол-Маерс Сквибб Компани Пирролотриазинанилиновые пролекарственные соединения, полезные в качестве ингибиторов киназы
EP1994017A2 (en) 2006-03-15 2008-11-26 4Sc Ag Novel heterocyclic nf-kb inhibitors
SI2010538T1 (sl) 2006-04-21 2013-06-28 Bristol-Myers Squibb Comapany POSTOPEK ZA PRIPRAVO ((1R),2S)-2-AMINOPROPIONSKE KISLINE-2-(4-(4- FLUOR-2-METIL-1H-INDOL-5-ILOKSI)-5-METILPIROL)2,1-f-(1,2,4-TRIAZIN- 6-ILOKSI)-1-METILETIL ESTRA
JP5185930B2 (ja) 2006-07-07 2013-04-17 ブリストル−マイヤーズ スクイブ カンパニー ピロロトリアジンキナーゼ阻害剤
WO2008012635A2 (en) 2006-07-26 2008-01-31 Pfizer Products Inc. Amine derivatives useful as anticancer agents
ES2393410T3 (es) 2006-08-09 2012-12-21 Bristol-Myers Squibb Company Pirrolotriazinas inhibidoras de quinasas
US7531539B2 (en) 2006-08-09 2009-05-12 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
WO2008027013A2 (en) 2006-08-29 2008-03-06 National Cancer Centre Combination of mtor antagonist and angiogenesis inhibitor for the treatment of cancer
JP2010508288A (ja) 2006-10-27 2010-03-18 ブリストル−マイヤーズ スクイブ カンパニー キナーゼ阻害剤として有用なヘテロサイクリックアミド化合物
WO2008057863A1 (en) 2006-11-01 2008-05-15 Bristol-Myers Squibb Company Therapeutic combination of a panher/vegfr2 kinase inhibitor and a platinum compound
CL2007003158A1 (es) 2006-11-02 2008-05-16 Astrazeneca Ab Procedimiento de preparacion de compuestos derivados de quinazolina o sus sales farmaceuticamente aceptables; compuestos intermediarios; procedimiento de preparacion.
JP5180967B2 (ja) 2006-11-03 2013-04-10 ブリストル−マイヤーズ スクイブ カンパニー ピロロトリアジンキナーゼ阻害剤
WO2008070616A2 (en) 2006-12-01 2008-06-12 University Of Utah Research Foundation METHODS AND COMPOSITIONS RELATED TO HIF-1α

Also Published As

Publication number Publication date
TW201035100A (en) 2010-10-01
AR074830A1 (es) 2011-02-16
EP2376491A1 (en) 2011-10-19
US8471005B2 (en) 2013-06-25
EP2376491B1 (en) 2015-03-04
ES2539620T3 (es) 2015-07-02
WO2010071885A1 (en) 2010-06-24
US20120028919A1 (en) 2012-02-02

Similar Documents

Publication Publication Date Title
HK1162520A1 (en) Pyrrolotriazines as alk and jak2 inhibitors alk jak2
HRP20180718T1 (hr) Oligopeptidni spojevi i njihova upotreba
HRP20130787T1 (xx) Imidazopiridazinkarbonitrili korisni kao inhibitori kinaza
ZA200906946B (en) Inhibitors of iap
IL211549A0 (en) Aminotriazolopyridines and their use as kinase inhibitors
EP2318395A4 (en) IPA INHIBITORS
ZA201100898B (en) Novel inhibitors
IL212755A0 (en) Pyrazinopyrazines and derivatives as kinase inhibitors
ZA201005618B (en) Iap inhibitors
RS56514B1 (sr) Disperzioni inhibitori hidroksifenilpiruvat dioksigenaze
ZA201101909B (en) Iap inhibitors
ZA201004765B (en) Inhibitors of iap
EP2231152A4 (en) THIENOPYRANONES AS KINASE INHIBITORS
EP2379076A4 (en) PHOSPHODIESTERASE HEMMER AND ITS USES
ZA201102837B (en) Phosphodiestarase inhibitors
GB0817429D0 (en) Enzyme inhibitors
PL386507A1 (pl) Kompozycja fotopolimeryzująca
GB201019387D0 (en) Inhibitors
GB0816125D0 (en) Novel inhibitors
GB0812443D0 (en) Enzyme inhibitors
GB0807056D0 (en) Enzyme inhibitors
IL191624A0 (en) Holds nails

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20181216